New pill targets Cancer's genetic weakness in advanced tumors
NCT ID NCT05451602
First seen Apr 30, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests a new oral drug, HEC169096, that blocks a cancer-driving protein called RET. It is for people with advanced thyroid cancer, non-small cell lung cancer, or other solid tumors that have not responded to standard treatments. The trial has two phases: first to find the safest dose, then to measure how well the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GuangDong Province Peoples Hospital
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.